Assistance Publique Hopitaux De Paris

At Assistance Publique Hopitaux De Paris in Creteil, the Néphrologie department is running a strong portfolio of studies in kidney disease, kidney transplantation, and related immune disorders. The research focuses on improving treatment options, protecting renal function, and refining care for patients with complex or treatment-resistant conditions.

• IgA nephropathy and lupus nephritis therapies aimed at reducing proteinuria and preserving kidney function
• APOL1-mediated kidney disease, focal segmental glomerulosclerosis, and other proteinuric kidney disorders
• Kidney transplantation studies on rejection prevention, CMV infection, and BKV viremia

This activity reflects a broad effort to improve both diagnosis and long-term outcomes for patients with chronic and transplant-related renal disease.

The site also has a major research focus on autoimmune disease and immune-mediated inflammation, studying conditions such as sarcoidosis, vasculitis, immune thrombocytopenia, and severe skin and connective tissue disorders. These trials are designed to test new treatment strategies and identify better ways to control persistent inflammation while reducing steroid use.

• Sarcoidosis, including pulmonary and extra-pulmonary forms
• ANCA-associated vasculitis, giant cell arteritis, and Takayasu arteritis
• immune thrombocytopenia, warm autoimmune haemolytic anaemia, and other rare immune disorders

Several studies at Assistance Publique Hopitaux De Paris explore whether targeted therapies can improve disease control in patients with difficult-to-treat immune conditions.

A large share of the clinical research portfolio is dedicated to hematology and blood cancers, including acute leukemia, lymphoma, multiple myeloma, and myelodysplastic syndromes. These studies are focused on testing new immunotherapies and combination approaches, with the goal of improving response rates and long-term survival.

• acute lymphoblastic leukemia and acute myeloid leukemia
• diffuse large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma
• multiple myeloma and other plasma cell disorders

The research environment includes studies of CAR-T cells, bispecific antibodies, and other advanced cancer therapies designed to improve outcomes in relapsed or high-risk disease.

The site conducts substantial work in digestive system diseases and liver disease, with trials in Crohn’s disease, ulcerative colitis, hepatocellular carcinoma, and fatty liver disease. Many of these studies aim to improve symptom control, reduce inflammation, and evaluate new options for patients with chronic or advanced gastrointestinal and liver conditions.

• Crohn’s disease and ulcerative colitis, including postoperative recurrence and treatment-resistant cases
• hepatocellular carcinoma, biliary tract cancer, and other liver tumors
• NASH, MASH, and alcohol-related liver disease

These trials at Assistance Publique Hopitaux De Paris are helping to evaluate new medicines and treatment strategies for both inflammatory bowel disease and complex liver disorders.

Clinical research in cardiovascular disease, stroke, and critical care addresses urgent conditions such as heart failure, myocardial infarction, septic shock, and ischemic stroke. The purpose of these studies is to improve survival, reduce complications, and support faster recovery in high-risk patients.

• heart failure, cardiogenic shock, and cardiac amyloidosis
• stroke, intracerebral haemorrhage, and acute thrombotic events
• sepsis, septic shock, and severe respiratory infections in intensive care

The cardiac and intensive care programs emphasize better emergency treatment and improved outcomes for patients with life-threatening illness.

The site also supports extensive research in solid tumors, including breast cancer, prostate cancer, bladder cancer, renal cell carcinoma, and colorectal cancer. These trials are designed to test newer treatment combinations, improve disease control, and evaluate approaches for patients with advanced or recurrent cancer.

• breast cancer, including hormone receptor-positive and triple-negative disease
• prostate cancer, including metastatic and high-risk recurrence settings
• bladder cancer, renal cell carcinoma, and colorectal cancer

Across these programs, Assistance Publique Hopitaux De Paris is evaluating therapies that may improve tumor response, delay progression, and support more personalized cancer care.